Literature DB >> 2199446

Recombinant HIV2 protease processes HIV1 Pr53gag and analogous junction peptides in vitro.

S Pichuantes1, L M Babé, P J Barr, D L DeCamp, C S Craik.   

Abstract

A synthetic DNA fragment encoding a protease precursor of the human immunodeficiency virus type 2 (HIV2) was cloned and expressed in bacteria and yeast. A recombinant plasmid encoding a hybrid polypeptide consisting of human superoxide dismutase and an HIV2 protease precursor of 113 amino acids was constructed for regulated intracellular expression in bacteria. Induction of this plasmid produced an autoprocessed form of the retroviral enzyme possessing the correct molecular weight. Overexpression and secretion of the protease from yeast was achieved with an expression vector encoding the yeast pheromone alpha-factor signal/leader sequence fused to a protease precursor of 115 amino acids. Amino-terminal sequence analysis confirmed that the viral enzyme exported from yeast was correctly processed from its precursor by cleavage of the predicted Ala-Pro peptide bond located at the NH2 terminus of the protease in the pol open reading frame. No additional amino acid residues were required at the COOH terminus of the protease for this autoproteolytic event. The HIV2 protease expressed in bacteria and yeast was active in an in vitro assay when tested on the HIV1 polyprotein precursor, myristylated Pr53gag. Two synthetic peptides representing junction sequences in the HIV1 gag-pol precursor were used to assay purified HIV2 protease. The enzyme exhibited a kcat/KM of 23.2 min-1 mM-1 on the HIV1 matrix-capsid junction peptide and a kcat/KM of 71.4 min-1 mM-1 on the protease-reverse transcriptase junction peptide. These rates show that the HIV2 enzyme is efficient at hydrolyzing the HIV1 peptide junctions, revealing the analogous nature of the substrate specificities of the two enzymes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2199446

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Rapid and specific detection of Sin Nombre virus antibodies in patients with hantavirus pulmonary syndrome by a strip immunoblot assay suitable for field diagnosis.

Authors:  B Hjelle; S Jenison; N Torrez-Martinez; B Herring; S Quan; A Polito; S Pichuantes; T Yamada; C Morris; F Elgh; H W Lee; H Artsob; R Dinello
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

2.  Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease.

Authors:  John M Louis; Rieko Ishima; Annie Aniana; Jane M Sayer
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

3.  Construction and characterization of chimeric BHIV (BIV/HIV-1) viruses carrying the bovine immunodeficiency virus gag gene.

Authors:  Yi-Xin Zhu; Chang Liu; Xin-Lei Liu; Wen-Tao Qiao; Qi-Min Chen; Yi Zeng; Yun-Qi Geng
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

4.  Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease.

Authors:  R L DesJarlais; G L Seibel; I D Kuntz; P S Furth; J C Alvarez; P R Ortiz de Montellano; D L DeCamp; L M Babé; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  A Direct Interaction with RNA Dramatically Enhances the Catalytic Activity of the HIV-1 Protease In Vitro.

Authors:  Marc Potempa; Ellen Nalivaika; Debra Ragland; Sook-Kyung Lee; Celia A Schiffer; Ronald Swanstrom
Journal:  J Mol Biol       Date:  2015-05-15       Impact factor: 5.469

6.  Expression of functional HIV-1 integrase in the yeast Saccharomyces cerevisiae leads to the emergence of a lethal phenotype: potential use for inhibitor screening.

Authors:  A B Caumont; G A Jamieson; S Pichuantes; A T Nguyen; S Litvak; C Dupont
Journal:  Curr Genet       Date:  1996-05       Impact factor: 3.886

7.  Colloidal aggregation and the in vitro activity of traditional Chinese medicines.

Authors:  Da Duan; Allison K Doak; Lyudmila Nedyalkova; Brian K Shoichet
Journal:  ACS Chem Biol       Date:  2015-02-09       Impact factor: 5.100

8.  Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases.

Authors:  L M Babé; J Rosé; C S Craik
Journal:  Protein Sci       Date:  1992-10       Impact factor: 6.725

9.  Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity.

Authors:  J R Rosé; L M Babé; C S Craik
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Comparative studies on retroviral proteases: substrate specificity.

Authors:  József Tözsér
Journal:  Viruses       Date:  2010-01-14       Impact factor: 5.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.